Terpos E - Search Results

1

Management of bone disease in multiple myeloma.

Terpos E, Berenson J, Raje N, Roodman GD. Terpos E, et al. Expert Rev Hematol. 2014 Feb;7(1):113-25. doi: 10.1586/17474086.2013.874943. Epub 2014 Jan 16. Expert Rev Hematol. 2014. PMID: 24433088 Review.

2

Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma.

Terpos E, Samarkos M, Meletis C, Apostolidou E, Tsironi M, Korovesis K, Mavrogianni D, Viniou N, Meletis J. Terpos E, et al. Int J Hematol. 2003 Nov;78(4):344-8. doi: 10.1007/BF02983560. Int J Hematol. 2003. PMID: 14686493

3

Biochemical markers of bone metabolism in multiple myeloma.

Terpos E. Terpos E. Cancer Treat Rev. 2006;32 Suppl 1:15-9. doi: 10.1016/s0305-7372(06)80004-6. Cancer Treat Rev. 2006. PMID: 16680833 Review.

4

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.

Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A. Dimopoulos MA, et al. Among authors: terpos e. Haematologica. 2006 Jul;91(7):968-71. Epub 2006 Jun 1. Haematologica. 2006. PMID: 16757414 Clinical Trial.

5

Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.

Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D, Terpos E. Zervas K, et al. Among authors: terpos e. Br J Haematol. 2006 Sep;134(6):620-3. doi: 10.1111/j.1365-2141.2006.06230.x. Epub 2006 Aug 1. Br J Haematol. 2006. PMID: 16889620 Free article.

6

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.

Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI. Terpos E, et al. Br J Haematol. 2006 Dec;135(5):688-92. doi: 10.1111/j.1365-2141.2006.06356.x. Br J Haematol. 2006. PMID: 17107351 Free article.

7

Myeloma bone disease and proteasome inhibition therapies.

Terpos E, Sezer O, Croucher P, Dimopoulos MA. Terpos E, et al. Blood. 2007 Aug 15;110(4):1098-104. doi: 10.1182/blood-2007-03-067710. Epub 2007 May 9. Blood. 2007. PMID: 17494860 Free article. Review.

8

Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.

Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, Berenson JR. Lipton A, et al. Among authors: terpos e. Clin Lymphoma Myeloma. 2007 Mar;7(5):346-53. doi: 10.3816/CLM.2007.n.011. Clin Lymphoma Myeloma. 2007. PMID: 17562244 Review.

9

Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.

Anargyrou K, Terpos E, Vassilakopoulos TP, Pouli A, Sachanas S, Tzenou T, Masouridis S, Christoulas D, Angelopoulou MK, Dimitriadou EM, Kalpadakis C, Tsionos K, Panayiotidis P, Dimopoulos MA, Pangalis GA, Kyrtsonis MC; Greek Myeloma Study Group. Anargyrou K, et al. Among authors: terpos e. Haematologica. 2008 Mar;93(3):451-4. doi: 10.3324/haematol.11852. Epub 2008 Feb 20. Haematologica. 2008. PMID: 18287135 Free article.

10

Novel anti-myeloma agents and angiogenesis.

Anargyrou K, Dimopoulos MA, Sezer O, Terpos E. Anargyrou K, et al. Among authors: terpos e. Leuk Lymphoma. 2008 Apr;49(4):677-89. doi: 10.1080/10428190701861686. Leuk Lymphoma. 2008. PMID: 18398734 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

746 results

Search Page